{"entity":{"id":"nct05718323","kind":"trial","name":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","aka":["RAISE"],"tldr":"A phase 2 trial of niraparib in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","summary":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC is a phase 2, interventional study registered as NCT05718323 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 44 participants, started 2023-12-20 and due to reach its primary completion in 2026-12. Interventions recorded: Niraparib. Conditions listed: SCLC,Extensive Stage; SLFN11-positive. Primary outcome: Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1). Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification)\". Sites: France, Germany, Italy, Spain, Switzerland. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05718323","url":"https://clinicaltrials.gov/study/NCT05718323"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["niraparib"],"companies":["etop-ibcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05718323","phase":"2","setting":"A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.","sponsor":"ETOP IBCSG Partners Foundation","enrolled":44,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05718323/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"company":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}